Background: Intestinal-type sinonasal adenocarcinoma (ITAC) is a rare tumour related to occupational wood dust exposure. Few studies have described recurrent genetic changes on a genome-wide scale. The aim of this study was to obtain a high resolution map of recurrent genetic alterations in ITAC.
Introduction
ITAC represents approximately 25% of all malignant sinonasal tumours. It arises almost exclusively in the ethmoid sinus and is strongly related to occupational wood and leather dust exposure (1) (2) (3) (4) (5) . The median age of onset lies between 50 and 60 years (1, 2, 6) . Four main histopathological subtypes are distinguished: papillary, colonic, solid and mucinous (alveolar goblet and signet ring) type, while a proportion of cases display more than one subtype (7) . ITAC tumours have a low tendency to develop lymphatic or distant metastases, however, local recurrences are very frequent and constitute the main cause of death (8) (9) (10) . The combined use of both surgery and radiotherapy is reported in the literature as the gold standard treatment (1) (2) . ITAC patients carry a poor prognosis, with a 5-year survival between 40% and 60% (6) (7) (8) (9) (10) (11) (12) (13) . Both disease stage and histopathological subtype are of prognostic value (1, 7, 14) .
The low incidence and the apparent lack of early lesions precursor to ITAC makes its study difficult. Hence, little is known about the genetic changes involved in the development of ITAC.
Most genetic studies on ITAC have focussed on specific genes involved in colorectal adenocarcinoma (CRC) because of their histological similarities. Comparing with CRC, these studies have indicated less frequent mutation in TP53 and activation of Wnt/β-catenin, while K-ras or BRAF mutations and microsatellite instability (MSI) are almost absent (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) . A number of studies reported EGFR overexpression in 20-32% of ITACs, and absence of mutations (25) (26) (27) . This demonstrates that ITAC is not genetically similar to CRC. Until the present moment, three genome-wide C o r r e c t e d p r o o f analyses using classical and microarray CGH have been published (28) (29) (30) . These studies showed that, with an exception for the papillary subtype, most ITACs carry complex karyotypes with hotspots of chromosomal gains at 5p, 7q, 8q, 12p and 20q, and losses at 4q, 5q, 8p, 17p and 18q. Either due to a low number of cases or to the absence of clinical and follow-up data, neither of these studies has come up with specific genetic events that are related to prognosis.
In this study, we have analysed 37 clinically well-described primary tumours by means of microarray CGH. For confirmation of the results, we performed MLPA (multiplex-ligation probe amplification), that included 65 cancer-related genes. In addition, we investigated the DNA ploidy status. Our aim was to obtain a high resolution map of recurrent genetic alterations and to correlate the genetic results with histopathological characteristics and clinical outcome.
Materials and methods

Tissue samples
All 37 cases analysed in this study arose in the ethmoid sinus Table 1 .
Flow cytometry
DNA ploidy was measured by flow cytometry as earlier described (30) . In short, fresh tissue was disaggregated mechanically, 
Microarray CGH
Tumour DNA as well as normal reference DNA from blood of female donors was extracted using a Qiagen extraction kit (Qiagen GmbH, Hilden, Germany). Microarray-CGH was carried out as described previously (31) . quality; since all tumours came from male patients, the chromosome X clones normally showed loss whereas the chromosome Y clones always showed gains. Normalization of the calculated ratios was done against the mode of all ratios. Graphics were plotted using a moving average of log2 ratios of 5 neighbouring clones. Gains and losses were defined as at least two neighbouring clones with deviations of 0.2 or more from log2 ratio=0.0.
High level amplification was considered when at least two neighbouring clones reached a log2 ratio of 1.0 or higher.
MLPA
MLPA was performed as described in detail previously (32) . Three kits were used, together analysing 65 cancer related genes distributed throughout the genome (SALSA P084, SALSA P005
and SALSA P105, MRC-Holland, Amsterdam, the Netherlands).
Each probe is composed of two parts that hybridize to adjacent target sequences in the DNA. Fourteen control experiments using normal DNA from 7 different donors were used to calculate median reference values and the standard deviations for every probe. Each tumour sample was analysed at least twice. For every gene, the relative copy number was calculated by dividing the average relative peak area of the tumour by the median relative peak area of the normal reference samples. When tumour/control ratio was higher than 1.2 and the standard deviation was > 1 was interpreted as gain. If the ratio was lower than 0.8 and the standard deviation was < 1 was interpreted as loss. It was interpreted as amplification when tumour/control ratio was higher than 2 and the standard deviation was also higher than 2.
Statistical analysis
The statistic analysis was carried out using Student's test, Pear- 
Results
Follow-up
Twenty-five patients received radiotherapy after surgery. During the time of follow-up, 6 patients developed metastasis and 20
had local recurrence. The 5 year overall survival of all patients 
Genetic results
DNA ploidy measurement was succesful in 34 tumours. Twentytwo (65%) tumours were aneuploid, ranging from 1.1 to 2.3, and 12 cases (35%) were diploid.
Microarray CGH analysis revealed DNA copy number alterations in all cases. An overview of all gains and losses observed in the 37 cases is given in Figure 2 . and TIMP2 at 17q25 (15 cases, 41%). Figure 3 gives an overview of all MLPA findings. A total of fourteen gene amplifications were detected, of which EGFR at 7p11 and MYC and RECQL4 at 8q24 occurred in two or more cases.
Clinico-pathological correlations
Diploid tumours had more favourable clinico-pathological features, including lower stage (50% versus 32% stage I+II), less 
Discussion
We have presented a genome-wide and detailed map of recurrent DNA copy number abnormalities in ITAC using microarray CGH, and this map was confirmed by MLPA analysis of 65 genes.
As in most solid tumours, a proportion of cases was diploid, displayed relatively few copy number alterations and in general Genetic studies on other tumours from the head and neck area such as squamous cell carcinoma (HNSCC) have reported frequent gains at 3q, 5p, 7p, 7q, 8q, 11q13, and 20q, and losses at 3p, 5q, 8p, 9p, 11qter, and 18q (33) . Our data on ITAC show notable differences with HNSCC, including losses at 3p and gains at 3q, 4q and 11q13. These regions are hardly affected in ITAC.
ITAC had more chromosomal changes in common with CRC, although gains at 5p, frequent in ITAC, are almost absent in CRC (34) .
Although many copy number alterations concerned large stret- (25) (26) (27) . Mutations in EGFR have not been reported for ITAC (25, 35) . EGFR plays an important role in the pathogenesis of both HNSCC and CRC, where it is expressed in up to 80% of tumours and it has been associated with poor survival and risk of relapse (36, 37) . In C o r r e c t e d p r o o f our series, EGFR copy number gains did not correlate with any of the clinico-pathological parameters and does not seem to be of prognostic value, confirming previous findings in ITAC (25) (26) (27) .
Nonetheless, EGFR can be of relevance for a possible treatment of ITAC with specific inhibitors, analogous to other tumours as lung cancer, colorectal cancer or head and neck cancer.
Amplifications at 8q24 at the location of cMYC were detected in two cases, however, 21 cases with gains indicated a a 1 Mbp common region of overlap at 8q24.3, harbouring PTP4A3 but not cancer-related genes as cMYC or FAK. The protein encoded by PTP4A3 belongs to a class of protein tyrosine phosphatases, which stimulates progression from G1 into S phase during mitosis. Interestingly, PTP4A3 overexpression in CRC has been related to the development of distant metastasis (38) . Gains of PTP4A3 were also detected in this study by MLPA, and was ob- (39, 40) . PTPN1
(or PTP1B) is a non-receptor protein-tyrosine phosphatase involved in many cellular signaling pathways, including EGFR and ERK. It may function as a suppressor but also as a promotor of neoplastic transformation. Gene amplification and protein overexpression in up to 72% of cases have been reported in breast cancer, especially in Her2/neu-positive tumours (41) . In our series of ITACs, gains of PTPN1 were found more frequently in tumours with intracranial invasion and with worse overall survival, although not statistically significant (Fisher exact p=0.078 and p=0.093, respectively).
Other high level amplifications were found at 8p11 (3 cases), 11p13, 19p13 and 6q23 (2 cases). A cancer-related gene at 8p11 may be FGFR1. Apart from the two cases with amplification, MLPA identified 6 other cases with FGFR1 copy number gain.
One previous study using FISH on sinonasal tumours revealed FGFR1 amplifications, but only in squamous carcinomas and not in ITAC (42) . The two amplifications at 6q23 included the site of the oncogene cMYB. MLPA did not confirm these amplifications, but did indicate 8 cases with copy number gain, suggesting it may play a role in ITAC. Activation of cMYB can also be caused by chromosomal translocation, as has been shown in adnoid cystic carcinoma (43, 44) , however, we are not aware of reports on cMYB translocations in ITAC. Finally, the amplications at 11p13
and 19p13 were not confirmed by MLPA, as none of the probes localized to these regions.
The 5-year overall survival of 41% in our series is low compared to other recently published series that reported 40-60% survival or better (6) (7) (8) (9) (10) (11) (12) (13) , although we observed a trend toward a better survival rate over the years ( Figure 1) . We believe the patients included in this study do reflect correctly the clinical characteristics known of ITAC, for example the prognostic value of histological subtype and disease stage (Figure 1 ). Therefore we were confident that our series allowed for univariant survival analysis according to the detected genetic alterations; multivariant analysis was not feasible because of the relatively low number of cases.
Chromosomal loss at 4q32-ter was notably correlated with worse clinical outcome (p=0.000), as did gains at 1q22, 3q29
and 6p22 to a lesser extent (Figure 4) . Unfortunately, none of the 65 genes in the MLPA analysis localized in these regions, and we cannot speculate on specific genes that may be the drivers. and has been related to poor prognosis in other studies (45) (46) (47) , however, more investigation is needed to clarify a possible role in ITAC. 
Conclusion
